Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system.
Calcitonin gene-related peptide (CGRP) just got another notch in its research belt. A recent review by Edvinsson and Edvinsson at Lund University dives into how CGRP acts in the trigeminovascular system—which is science-speak for the nerve network that’s front and center in headache and migraine research.
Nat Rev Neurol
by Edvinsson L, Edvinsson JCA
“Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system. Edvinsson L(1), Edvinsson JCA(2). Author information: (1)Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University, Lund, Sweden. Lars.Edvinsson@med.lu.se. (2)Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University, Lund, Sweden. Conflict of interest statement: Competing interests: The authors declare no competing interests.”
Key takeaway: CGRP is a big deal for anyone studying pain signaling, especially in the context of migraines. The review pulls together a decade’s worth of work on how this neuropeptide helps transmit pain signals through the trigeminovascular pathway. When CGRP gets released in this system, it ramps up the sensitivity of pain receptors, making neurons more likely to fire off warning shots (a.k.a. pain).
For researchers, CGRP is a goldmine:
It’s a reliable marker for studying how pain starts and spreads in the nervous system
It helps pinpoint how and why certain headaches—like migraines—become so intense
It’s a test case for developing new peptide-based research compounds
You’re not limited to CGRP, either. The review hints at a broader role for peptides in modulating pain pathways, pushing the boundaries for what peptide research can uncover. That means more targets, more hypotheses, and more ways to build out your research portfolio.
If you’re digging into pain models, migraines, or just want to see how peptides can tweak nervous system activity, CGRP should be on your radar. Check out the peptide research index for more on CGRP and related compounds.
The bottom line: Peptides aren’t just molecular messengers—they’re active players in the pain game, and the trigeminovascular system is the latest arena. Keep an eye on this space.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.